TB-500 benefits and side effects: what is actually studied

If you have researched peptides for a stubborn tendon, a muscle tear, or a joint that will not settle down, “TB-500” comes up fast, usually alongside a confident claim that it rebuilds soft tissue. The claim runs far ahead of the evidence. TB-500 is a real, well-defined molecule with a genuinely interesting biology, but almost everything sold to you about it is extrapolated from animal experiments on a different, larger protein, and the parts that have been tested in people were tested for eye and heart conditions, not injuries. This guide separates the things that usually get blended together: what TB-500 actually is, what benefits are claimed for it, what the science has genuinely shown (and in which species), what is known about side effects, and what users report. Every factual claim here is linked to a primary or peer-reviewed source.

What is TB-500, and how is it related to thymosin beta-4?

TB-500 is a short synthetic peptide that copies one active region of thymosin beta-4, not the whole protein. Thymosin beta-4 (often written Tβ4) is a natural molecule your own cells make: a chain of 43 amino acids that is, in the words of a 2022 review, a peptide whose “biological activity is determined by encoded gene fragments,” with different stretches of the chain doing different jobs (Progress on the Function and Application of Thymosin β4, PMC). TB-500, as it is sold, is not that full 43-amino-acid protein. Analytical chemists who examined commercial TB-500 for anti-doping purposes identified it as the N-terminally acetylated fragment spanning residues 17 to 23 of thymosin beta-4, the seven-amino-acid sequence Ac-LKKTETQ, in a 2012 study in the journal Drug Testing and Analysis (Esposito et al., 2012).

That distinction is not academic hair-splitting; it changes how you should read every study you see cited. The 17-to-23 region is one of the peptide’s known active sites, the same 2022 review attributes angiogenesis, the growth of new blood vessels, and hair-follicle effects to “amino acids 17-23” specifically (PMC). So the fragment is a plausible piece to isolate. But “a plausible active fragment” and “the molecule that was tested in a given study” are different things. When a vendor page lists impressive research, it is almost always research on full-length thymosin beta-4, and the evidence for the isolated TB-500 fragment behaving identically in a human body is much thinner than the citations imply.

How is thymosin beta-4 thought to work?

Thymosin beta-4 works mainly by binding actin, the internal protein scaffolding that lets cells hold their shape and move. It is the major actin-sequestering molecule in the cells of higher organisms, and that single role is the engine behind most of its proposed effects: by controlling the pool of actin available for assembly, it influences how readily cells migrate. A landmark 2005 review in Trends in Molecular Medicine framed it exactly this way in its title, an “actin-sequestering protein” that “moonlights to repair injured tissues”, and described its role in dermal and corneal wound healing and its potential in the remodeling of tissues after low-oxygen injuries such as heart attack and stroke (Goldstein, Hannappel, and Kleinman, 2005).

Beyond moving cells around, the parent protein has been reported to do several related things in laboratory systems. The 2022 review catalogs its promotion of new blood-vessel formation, its support of cell survival, and its dampening of inflammation, and it maps these to different regions of the chain: the first four amino acids are associated with anti-inflammatory and antifibrotic effects, the first fifteen with reducing cell death, and the 17-to-23 segment with angiogenesis (PMC). In plain terms, the mechanistic story people find compelling is real as a piece of cell biology: a molecule that helps cells migrate, encourages capillaries, and dials down inflammation is exactly the kind of thing you would want during healing. The gap is between that mechanism and a demonstrated, dosed, safe effect on a human injury, a gap the mechanism alone cannot close.

What are the claimed benefits of TB-500?

TB-500 is marketed and discussed mainly for faster soft-tissue healing: tendons, ligaments and muscle tears, plus general recovery from training. Those claims map onto three effects reported for the parent protein in laboratory and animal work: cell migration into an injury, new blood-vessel growth, and reduced inflammation. Here is how each claimed benefit lines up with the evidence covered on this page.

The table’s pattern is the key point: the only human evidence is for the full protein in the eye, and none of it is for the injuries TB-500 is sold for.

What does the animal research on tissue healing show?

The strongest signals for thymosin beta-4 come from animal and cell experiments, and they are genuinely interesting on their own terms. The clearest example is cardiac. In a 2014 study in the American Journal of Physiology – Heart and Circulatory Physiology, researchers gave thymosin beta-4 to mice after a myocardial infarction and saw a striking effect on survival: over the first seven days after the heart attack, 56.3 percent of untreated mice died of left-ventricular rupture, compared with 22.7 percent of the treated mice, and by five weeks the treated animals had less ventricular dilation, better measured heart function, and more new capillaries in the injured area (Peng et al., 2014, PMC). That is a large, real difference, in mice.

The same pattern shows up across other tissues. In rodent and cell models, thymosin beta-4 has been reported to speed skin-wound closure, support corneal healing, and drive the cell migration and blood-vessel growth that healing depends on, which is why the 2005 review discussed it as a candidate for dermal and corneal wound healing (Goldstein et al., 2005). The consistency of these preclinical results is what gives the peptide its reputation. But two cautions belong right next to that reputation. First, animal-to-human translation in tissue healing fails far more often than it succeeds; a survival benefit in a mouse heart is a reason to run a human trial, not a substitute for one. Second, and specific to this topic, almost none of this work used the TB-500 fragment. It used the full protein. The tendon-and-muscle recovery story that TB-500 is marketed on is, at the level of hard data, an extrapolation twice over: from full protein to fragment, and from animals to people.

What human evidence actually exists?

Human evidence for thymosin beta-4 is limited and comes almost entirely from eye and heart studies, not injury recovery. The full protein has reached clinical trials: the 2022 review notes that phase I and phase II trials have been conducted in conditions including acute myocardial infarction, dry-eye syndrome, epidermolysis bullosa, and pressure ulcers, and that no dose-limiting toxicities or serious adverse events were reported in the early-phase safety work (PMC). One registered example of that development is a phase 2 trial of injectable thymosin beta-4 (RGN-352) in ST-elevation heart-attack patients after angioplasty, though that specific study was withdrawn before it enrolled anyone, so it produced no results (ClinicalTrials.gov NCT01311518).

The best-documented human results are ophthalmic. In a phase 2 randomized, double-masked, vehicle-controlled trial of a thymosin beta-4 eye drop for severe dry-eye disease, published in Cornea in 2015, the treated group showed a 35.1 percent reduction in ocular discomfort compared with vehicle (P = 0.0141) and a 59.1 percent reduction in total corneal fluorescein staining (P = 0.0108) (Sosne, Dunn, and Kim, 2015). That is a real, statistically significant human result, but it was a very small study, it used a topical eye drop, and it tested the full protein for an eye condition. It says essentially nothing about injecting a fragment for a torn hamstring. There is, as of this writing, no published human clinical trial showing that TB-500 speeds recovery of a tendon, a muscle, or a ligament in a person. Anyone presenting the peptide as a proven injury treatment is describing animal data, or unrelated eye and heart data, as if it were orthopedic proof. PeptideAgent’s TB-500 profile keeps the same distinction when it grades the evidence: the full-length thymosin beta-4 trials do not count toward the fragment’s grade.

TB-500 versus thymosin beta-4: what has actually been studied?

TB-500 and thymosin beta-4 are related but not interchangeable, and the evidence behind them differs in ways that matter for any recovery decision. The table below separates the marketed fragment from the studied protein across the dimensions that determine how much weight either deserves. It is a map of what is known and where, not a scorecard, because neither has the human injury data that a scorecard would require.

The row that reframes the whole comparison is “human clinical trials for injury recovery”: both columns read “none.” The differences above are real biology, but they sit on top of a shared foundation of preclinical-only evidence for the use people actually care about here.

Is TB-500 banned in sport?

Yes, TB-500 and thymosin beta-4 are prohibited in sport at all times, both in and out of competition. The World Anti-Doping Agency’s 2026 Prohibited List covers peptide hormones, growth factors, related substances, and mimetics under class S2, and its growth-factors provision names thymosin-β4 and its derivatives, such as TB-500, among the substances that affect muscle, tendon, or ligament regeneration and vascularization. The 2012 analytical study that first characterized commercial TB-500 flagged the same doping concern in its title, presenting the 17-to-23 fragment as one “identified in TB-500, a product suspected to possess doping potential” (Esposito et al., 2012).

For any athlete tested by WADA, USADA, the NCAA, or a WADA-compliant federation, the practical meaning is simple: using TB-500 risks a sanction, and the “research use only” label on the vial changes none of that. If you compete under any drug-testing program, this is not a gray area but a bright line. For a fuller treatment of the sport rules and the athletes affected, see our companion guide on whether recovery peptides are banned in sport.

What are the side effects of TB-500?

No consistent side-effect profile has been established for TB-500 in people, because the long-term human safety data does not exist. Early-phase trials of the full thymosin beta-4 protein reported no dose-limiting toxicities, which is reassuring as far as it goes (PMC), but “no obvious harm in a small, short safety study of the parent protein” is a long way from “safe to inject the fragment repeatedly at home for months.” Nobody has established a safe dose, a safe duration, or the long-term consequences of the fragment in healthy people using it for recovery.

Two further unknowns depend on how TB-500 is obtained. When it is bought as a research chemical rather than a medicine, the vial is not required to be sterile, is not required to contain the dose on the label, and is not required to be free of contaminants or the wrong peptide entirely, the “research use only” designation exists precisely to sidestep those requirements. Forensic analysis bears that concern out: a peer-reviewed study of the falsified peptide products most often acquired from illegal internet pharmacies found high variation in the amount of drug per unit and low purity, between 5 and 75 percent for cysteine-containing peptides, along with toxic elemental impurities, arsenic and lead, at concentrations up to ten times the international toxicity limit for injectable drugs (Janvier et al., 2018). Sterility is not assured either, and an injected non-sterile product carries a real infection risk. Layered on top is the biological uncertainty: a molecule that encourages new blood-vessel growth is being studied for that very reason, but unregulated, unsupervised angiogenesis is not self-evidently benign, and no monitoring is happening when nobody is supervising its use. None of this means the peptide is proven dangerous; it means the safety questions that a clinical evaluation is designed to answer are, for TB-500, simply unanswered.

What do people using TB-500 report?

On social media TB-500 is almost always discussed as the recovery half of a stack with BPC-157. Our July 2026 snapshots of public posts on X (16 posts in each of two samples) found users describing a return to weight training after a torn pectoral ligament, a rotator cuff tear or a fractured humerus while on peptide protocols, usually alongside BPC-157 and sometimes other substances. A skeptical minority said they were not convinced TB-500 added anything, or had stopped buying the combined product and preferred BPC-157 alone. The most technical thread echoed the point this page started with: several users argued that products labeled TB-500 often contain the full 43-amino-acid thymosin beta-4 rather than the 7-amino-acid fragment, which they said changes how it behaves. That claim comes from the users, not from testing we have seen, but it is a reminder that the label on a research product may not match the molecule inside. These are individual, unverified accounts and are not evidence of effect. For why the two are paired, see our guide to BPC-157 and TB-500 together, and for the combined product, our Wolverine stack explainer.

The honest next step

If your real goal is a healthy tendon, muscle, or joint, the most useful move is not to gamble on an unverified vial of a peptide whose injury evidence is preclinical and which is banned in sport. It is to bring that goal to a licensed provider who can weigh the options with the strongest evidence for your injury, which may be structured rehabilitation, an established treatment, or watchful management. A provider may well recommend something other than the peptide you came in asking about, and that is the value of clinical supervision. The Recovery Dose exists to help you make that decision on evidence rather than on marketing.

Key takeaways

• TB-500 is a synthetic seven-amino-acid fragment (Ac-LKKTETQ, residues 17–23) of thymosin beta-4, the natural 43-amino-acid actin-binding protein, not the full protein most cited studies actually used.
• Thymosin beta-4’s proposed benefits come from its actin-binding role in cell migration, blood-vessel growth, and inflammation control, shown mainly in mouse, rat, and cell studies.
• The clearest results, including a survival benefit after induced heart attack, are in animals; a favorable animal result is a reason to run a human trial, not a substitute for one.
• Human trials exist for the full protein in eye and heart conditions, not injuries, and there is no published human trial showing TB-500 speeds recovery of a tendon, muscle, or ligament injury in a person.
• No consistent side-effect profile has been established in people; early trials of the full protein reported no dose-limiting toxicities, and research-chemical products carry their own purity and sterility risks.
• TB-500 is prohibited in sport at all times.

TB-500 status: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. How peptide status works.

Educational information only, not medical advice. Scientific and anti-doping statements are sourced to the peer-reviewed literature, ClinicalTrials.gov and the WADA list linked above, checked as of October 12, 2026.